Retatrutide
Conveniently located to serve the areas of Berkeley, Oakland and Bay Area, CA
Retatrutide* is an experimental weight loss medication that is in development to potentially work on three key hormonal pathways to help regulate appetite, improve metabolic function, and support long-term weight loss goals. Retatrutide is thought to activate the GLP-1, GIP, and glucagon receptors. This separates it from other weight loss medications, which tend to only activate the GLP-1 and/or GIP receptors. By targeting three hormone receptors, it is thought to have the potential to enhance satiety after consuming smaller portions, slow digestion, and improve blood sugar control.
Currently, this treatment is still in developmental phases, but clinical trials have shown promising results; early studies have conjectured that retatrutide could perhaps change the way medically-assisted weight loss is approached. (1) Like other weight loss medications, it would be administered as a once-weekly injection, inserted subcutaneously into areas such as the arms, thighs, or abdomen.
Located in Berkeley, California, Nubo Spa has developed a reputation as one of the Bay Area’s leading health and wellness destinations. We strive to help patients achieve their ideal body image and optimize their health through our fully customized medically-assisted weight loss program.
If you are looking to learn more about Retatrutide, schedule a personal consultation with our staff today by contacting our staff online or calling (510) 637-9194.
*The information on this page is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug still undergoing clinical trials and is not FDA-approved. Nubo Spa does not currently offer Retatrutide. Please consult a licensed healthcare provider before starting any medical weight loss treatment.
References
- Alaa Abdrabou Abouelmagd, Amro Mamdouh Abdelrehim, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor University Medical Center Proceedings. 2025;38(3):291-303. doi:https://doi.org/10.1080/08998280.2025.2456441
